NASDAQ:ENTX - Entera Bio News Headlines

$3.65
+0.06 (+1.67 %)
(As of 07/21/2019 06:30 AM ET)
Today's Range
$3.65
Now: $3.65
$3.77
50-Day Range
$2.72
MA: $3.49
$3.90
52-Week Range
$2.54
Now: $3.65
$6.40
Volume627 shs
Average Volume11,233 shs
Market Capitalization$41.72 million
P/E Ratio0.28
Dividend YieldN/A
BetaN/A

Headlines

Entera Bio (NASDAQ ENTX) News Headlines

Source:
DateHeadline
Critical Comparison: Entera Bio (NASDAQ:ENTX) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI)Critical Comparison: Entera Bio (NASDAQ:ENTX) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI)
www.americanbankingnews.com - July 20 at 6:09 PM
Entera Bio Ltd (NASDAQ:ENTX) Short Interest Down 50.0% in JuneEntera Bio Ltd (NASDAQ:ENTX) Short Interest Down 50.0% in June
www.americanbankingnews.com - July 12 at 10:45 AM
What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?
finance.yahoo.com - July 11 at 3:41 PM
Rubius Therapeutics (NASDAQ:RUBY) versus Entera Bio (NASDAQ:ENTX) Critical ContrastRubius Therapeutics (NASDAQ:RUBY) versus Entera Bio (NASDAQ:ENTX) Critical Contrast
www.americanbankingnews.com - July 6 at 10:16 AM
Maxim Group Initiates Coverage on Entera Bio (NASDAQ:ENTX)Maxim Group Initiates Coverage on Entera Bio (NASDAQ:ENTX)
www.americanbankingnews.com - July 5 at 7:55 PM
Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTHEntera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH
finance.yahoo.com - July 2 at 11:34 AM
From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & SullivanFrom Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan
finance.yahoo.com - July 1 at 11:29 AM
Entera Bio Reports First Quarter 2019 Financial Results and Operating UpdateEntera Bio Reports First Quarter 2019 Financial Results and Operating Update
finance.yahoo.com - June 27 at 11:33 AM
Entera Bio Ltd (NASDAQ:ENTX) Sees Significant Increase in Short InterestEntera Bio Ltd (NASDAQ:ENTX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - June 26 at 6:21 PM
Entera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call TranscriptEntera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 29 at 12:33 PM
Entera Bio Reports 2018 Annual Financial Results and Operating UpdateEntera Bio Reports 2018 Annual Financial Results and Operating Update
finance.yahoo.com - March 28 at 12:28 PM
Entera Bio Announces 20-F FilingEntera Bio Announces 20-F Filing
finance.yahoo.com - March 28 at 12:28 PM
Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28
finance.yahoo.com - March 27 at 12:12 PM
Entera Bio Announces a Transition in the Chief Financial Officer PositionEntera Bio Announces a Transition in the Chief Financial Officer Position
finance.yahoo.com - March 7 at 11:31 AM
Entera Bio advancing osteoporosis candidate EB-613; shares up 3%Entera Bio advancing osteoporosis candidate EB-613; shares up 3%
seekingalpha.com - January 31 at 3:34 PM
Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in OsteoporosisEntera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis
finance.yahoo.com - January 31 at 10:48 AM
Entera Bio Reports Third Quarter 2018 Financial Results and Operating UpdateEntera Bio Reports Third Quarter 2018 Financial Results and Operating Update
finance.yahoo.com - January 22 at 10:13 AM
Entera Bio Ltd.Entera Bio Ltd.
www.barrons.com - January 17 at 10:46 AM
Entera Bio Appoints Gerald M. Ostrov to Board of DirectorsEntera Bio Appoints Gerald M. Ostrov to Board of Directors
finance.yahoo.com - January 10 at 10:42 AM
Frost & Sullivan Publishes Immediate Report on DNA Biomedical Solutions Ltd.Frost & Sullivan Publishes Immediate Report on DNA Biomedical Solutions Ltd.
www.prnewswire.com - December 12 at 10:58 AM
Entera shares jump 11.5% on news of collaboration with AmgenEntera shares jump 11.5% on news of collaboration with Amgen
finance.yahoo.com - December 11 at 3:28 PM
Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious IllnessesEntera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses
finance.yahoo.com - December 11 at 8:34 AM
Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with HypoparathyroidismEntera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
finance.yahoo.com - November 8 at 3:21 PM
Entera Bio Appoints Two New External Independent Members to the Board of DirectorsEntera Bio Appoints Two New External Independent Members to the Board of Directors
finance.yahoo.com - October 2 at 3:16 PM
Entera Bio Appoints Dr. Arthur Santora as Chief Medical OfficerEntera Bio Appoints Dr. Arthur Santora as Chief Medical Officer
finance.yahoo.com - September 21 at 3:16 PM
Entera Bio Reports Second Quarter 2018 Financial Results and Operating UpdateEntera Bio Reports Second Quarter 2018 Financial Results and Operating Update
finance.yahoo.com - September 10 at 10:33 AM
Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of DirectorsEntera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors
feeds.benzinga.com - August 9 at 12:59 PM
Entera Bio Ltd. Announces Pricing of Initial Public OfferingEntera Bio Ltd. Announces Pricing of Initial Public Offering
finance.yahoo.com - August 7 at 8:40 AM
Entera Bio Ltd. Announces Closing of Initial Public OfferingEntera Bio Ltd. Announces Closing of Initial Public Offering
finance.yahoo.com - August 7 at 8:40 AM
Entera Bio Completes Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism PatientsEntera Bio Completes Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients
finance.yahoo.com - August 7 at 8:40 AM
Entera Bio sets IPO terms; to offer 5 million shares priced at $10 to $12 eachEntera Bio sets IPO terms; to offer 5 million shares priced at $10 to $12 each
finance.yahoo.com - January 13 at 8:03 AM
This page was last updated on 7/21/2019 by MarketBeat.com Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel